Article Text

Download PDFPDF
Risk of DKA with SGLT2 inhibitors

Abstract

Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.

  • Health Care Quality
  • Access
  • and Evaluation
  • Drug-Related Side Effects and Adverse Reactions

Statistics from Altmetric.com

Footnotes

  • Overview of Douros A, Lix LM, Fralick M, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis. Ann Intern Med 2020;173:417–25.

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.